A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

ABSTRACT: Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53-HDM2 inhibitor NVP-CGM097, currently under evaluation in clinical trials. By intersecting high-throughput cell line sensitivity data with genomic data, we have identified a gene expression signature consisting of 13 up-regulated genes that predicts for sensitivity to NVP-CGM097 in both cell lines and in patient-derived tumor xenograft models. Interestingly, these 13 genes are known p53 downstream target genes, suggesting that the identified gene signature reflects the presence of at least a partially activated p53 pathway in NVP-CGM097-sensitive tumors. Together, our fi

SUBMITTER: Jeay S 

PROVIDER: S-EPMC4468608 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature